Germany's Stratec Q1 revenue falls, posts loss per share

Stratec SE

11/05/2026 06:05

Overview

Germany diagnostics systems maker's Q1 revenue fell 11.5% yr/yr, adjusted EPS turned negative

Company attributes declines to lower Service Parts and Consumables sales, in line with planning

Outlook

Stratec confirms 2026 guidance for constant-currency sales growth in medium to high single digits

Company sees 2026 adjusted EBIT margin around 2025 level of 10.0%

Result Drivers

SERVICE PARTS AND CONSUMABLES - Lower sales in this segment due to logistics optimization measures at customers weighed on overall revenue

PRODUCT MIX - Lower share of high-margin Service Parts and Consumables sales contributed to the decline in operating profitability

Company press release: ID:nEQ2lR81ga

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 53.43 mln
Q1 Adjusted EPS
-EUR 0.09
Q1 Adjusted Net Income
-EUR 1.11 mln
Q1 Adjusted EBIT
EUR 691,000
Q1 Adjusted EBIT Margin
1.30%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Stratec Se is €30.50, about 72.3% above its May 8 closing price of €17.70

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)